Journal
CLINICAL THERAPEUTICS
Volume 42, Issue 10, Pages 1850-1852Publisher
ELSEVIER
DOI: 10.1016/j.clinthera.2020.08.006
Keywords
COVID-19; inflammation; mast cells; platelet-activating factor; thromboses
Categories
Ask authors/readers for more resources
Recent articles have reported elevated markers of coagulation, endothelial injury, and microthromboses in lungs from deceased patients with coronavirus 2019 (COVID-19). Platelets are critical in the formation of thrombi, and their most potent trigger is platelet activating factor (PAF). PAF is produced by cells involved in host defense, and its biological actions bear similarities with COVID-19 disease manifestations, including pulmonary microthromboses and inflammation, possibly via activation of mast cells. The histamine(1) receptor antagonist rupatadine was developed to have anti-PAF activity and inhibits activation of human mast cells in response to PAF. Rupatadine could be repurposed for COVID-19 prophylaxis. (C) 2020 Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available